Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"Zacks Investment Research • 08/31/26
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great ChoiceZacks Investment Research • 08/28/26
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and PrecigenZacks Investment Research • 08/27/26
NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?Zacks Investment Research • 08/24/26
Is Halozyme Therapeutics (HALO) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 08/13/26
Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock UpZacks Investment Research • 08/07/26
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/06/26
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass EstimatesZacks Investment Research • 08/06/26
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCEPRNewsWire • 08/06/26
Halozyme: Unique Business Model -- Adds A Powerful Leavening Element To Any Biotech PortfolioSeeking Alpha • 07/29/26
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® TechnologyPRNewsWire • 07/20/26
Inflation Cools But US-Iran Tensions Rise: 4 Value Stocks to Buy NowZacks Investment Research • 07/16/26